Patrick A. Treseler, MD, PhD

Seattle University, Seattle, WA, B.S., 1975-1979, Biology and Chemistry
Duke University, Durham, NC, M.D. and Ph.D., 1979-1985, Medicine/Immunology
Duke University Medical Center, Durham, NC, 1986, Internal Medicine
Brigham and Women’s Hospital, Boston, MA, 1986-1992, Anatomic & Clinical Pathology

• 1991-1992
  Dept. of Pathology, Attending Staff Pathologist, Brigham & Women's Hosp., Boston, MA
• 1992-1995
  Eastside Pathology, Inc., Staff Pathologist, Redmond, WA
• 1995-present
  Dept. of Pathology, Attending Staff Pathologist and Associate Director of Surgical Pathology, University of California San Francisco, San Francisco, CA

• 1975
  National Merit Scholarship Semi-Finalist and Finalist
• 1975
  Phi Beta Kappa Outstanding Scholastic Achievement Award
• 1975
  Bausch and Lomb Honorary Science Award
• 1975
  American Legion Distinguished Scholastic Achievement Award
• 1975
  C.R.C. Freshman Chemistry Achievement Award
• 1978
  Alpha Sigma Nu (National Jesuit Honor Society)
• 1979
  Seattle University President's Award (Top Graduating Senior)
• 1979-1985
  Fellow, Duke University Medical Scientist Training Program
• 1990
  N.I.H. Individual National Research Service Award

• Treseler, P.A., and Clark, O.H. Prognostic factors in thyroid carcinoma. Surg Oncol Clin North Am. 6: 555-598; 1997.
• Russo, D., Wong, M.G., Costante, G., Chiefari, E., Treseler, P.A., Arturi, F., Filetti, S, and Clark, O.H. A val-677 activating mutation of the thyrotropin receptor in a Hurthle cell thyroid carcinoma associated with thyrotoxicosis. Thyroid 9: 13-17; 1999.
• Kebebew, E., Treseler, P.A., Siperstein, A.E., Duh, Q.-Y., and Clark, O.H. Normal thyroid pathology in patients undergoing thyroidectomy for finding a RET gene germline mutation: a report of three cases and a review of the literature. Thyroid 9: 127-131; 1999.
• J.E. Vaquerano, Cadbury, P., Treseler, P., Sagebiel, R., and Leong, S.P.L. Regression of in-transit melanoma of the scalp with intralesional recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF); a brief report. Arch Dermatol 135: 1276-1277; 1999.
• Perrier, N.D., Ituarte, P.H.G., Treseler, P., D"Avanzo, A., Siperstein, A., Duh, Q.Y., and Clark, O.H. Classification and treatment of follicular thyroid neoplasms are discordant between and within medical specialties. Surgery 126: 1063-1069; 1999.
• Leong, S.P.L., Morita, E., Treseler, P., and Wong, J. Multidisciplinary approach to selective sentinel lymph node mapping in breast cancer. Breast Cancer 7: 105-113; 2000.
• Thelmo, M.C., Sagebiel, R.W., Treseler, P.A., Morita, E.T., Nguyen, L.H., Kashani-Sabet, M., and Leong, S.P.L. Evaluation of sentinel lymph node status in spindle cell melanoma. J Am Acad Derm In press.
• Treseler, P.A., and Tauchi, P.S. Pathologic analysis of the sentinel lymph node. Surg Clin North Am 80: 1695-1719; 2000.
• Leong, S.P.L., Nwakanma, L., Achtem, T.A., Morita, E., Sokol, S.C., Treseler, P., Kuerer, H.M., Hwang, E., and Esserman, L. Evolving techniques in the identification and mapping of breast cancer sentinel lymph nodes. Submitted for publication.
• Leong, S.P.L., Achtem, T., Steinmetz, I., Habib, F.A., Abbey, K.R., Miller, J., Allen, R.E., Morita, E., Treseler, P., Mraz, S., Kashani-Sabet, M., and Sagebiel, R. Micrometastases in sentinel lymph nodes is a strong predictor of recurrence and death from metastatic melanoma. Submitted for publication.
• Jensen, R.H., Tiirikainen, M., You, L., Treseler, P., and Jablons, D.M. Genomic alterations in human malignant mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q. Submitted for publication.
• You, L., Yang, C.T., Zang, K., Xie, J.W., Treseler, P., Moody, T., McCormick, F., and Jablons, D.M. Profiling of differentially expressed genes in human malignant pleural mesothelioma. Submitted for publication.
• Treseler, P.A., Song, J., Ituarte, P.H.G., David, G., Clary-Macy, C., You, L., and Jablons, D.M. Immunoreactivity for p53 and bcl-2 proteins predicts survival in patients with malignant pleural mesothelioma. Submitted for publication.
• D'Avanzo, A., Ituarte, P., Treseler, P., Kebebew, E., Wu, J., Wong, M., Duh, Q.-Y., Siperstein, A.E., and Clark, O.H.: Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Submitted for publication.
• Alsanea, O., Wada, N., Ain, K., Wong, M., Taylor, K., Ituarte, P., Treseler, P., Weier, H.-U., Freimer, N., Siperstein, A.E., Duh, Q.-Y., Takami, H., and Clark, O.H.: Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer: a multi-center study. Submitted for publication.
• Kebebew, E., Treseler, P.A., Duh, Q.-Y., Clark, O.H.: The helix-loop transcription factor, ID1, is overexpressed in medullary thyroid cancer. Submitted for publication.